Age-Related Macular Degeneration - Global Strategic Business Report

The global market for Age-Related Macular Degeneration was valued at US$10.9 Billion in 2025 and is projected to reach US$18.4 Billion by 2032, growing at a CAGR of 7.8% from 2025 to 2032. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions.

Global Age-Related Macular Degeneration Market - Key Trends & Drivers Summarized

Why Is the Prevalence of Age-Related Macular Degeneration Increasing Globally?

The rising global prevalence of age-related macular degeneration is driven by the rapidly aging population and increasing life expectancy. As the proportion of elderly individuals grows, the incidence of AMD, a leading cause of irreversible vision loss in older adults, continues to escalate. Lifestyle factors such as unhealthy diets, smoking, and prolonged exposure to blue light from digital screens have also contributed to the rising burden of AMD worldwide. Moreover, the growing awareness about eye health and the increasing frequency of routine eye examinations are leading to earlier diagnosis and treatment of AMD, thereby expanding the market for therapeutic interventions. Healthcare organizations and governments are intensifying efforts to educate the public about the importance of early detection and preventive measures, which is positively impacting the demand for AMD-related diagnostics and treatments.

How Are Advances in Treatment Options Shaping the AMD Market?

Innovative treatment approaches and the introduction of novel therapies are significantly transforming the AMD market landscape. Anti-vascular endothelial growth factor (anti-VEGF) injections continue to dominate the treatment paradigm for wet AMD, offering improved vision outcomes and slowing disease progression. However, recent advancements in gene therapy, stem cell research, and sustained drug delivery systems are offering new hope for patients with both wet and dry AMD. Emerging therapies, such as complement inhibitors and oral treatments targeting inflammation and oxidative stress, are gaining traction as potential disease-modifying solutions. Additionally, the development of longer-acting biologics and implantable drug delivery devices is improving patient compliance by reducing the frequency of injections. As pharmaceutical companies continue to invest heavily in R&D, the pipeline for AMD treatments remains robust, promising a shift towards more personalized and effective therapeutic options.

What Are the Key Market Challenges and Opportunities?

Despite the significant progress in AMD treatment, challenges such as high treatment costs, limited access to advanced therapies, and the absence of a definitive cure for dry AMD continue to pose hurdles to market growth. The high price of anti-VEGF injections, coupled with the need for frequent administration, places a financial burden on patients and healthcare systems, particularly in low- and middle-income countries. Additionally, the lack of effective therapies for geographic atrophy, an advanced form of dry AMD, remains an unmet need, driving researchers to explore novel therapeutic targets. However, these challenges present opportunities for innovation, with market players focusing on cost-effective solutions and patient-friendly drug delivery mechanisms. The increasing adoption of teleophthalmology and artificial intelligence-based screening tools is also opening new avenues for early detection and remote monitoring, enhancing accessibility and patient outcomes.

What Are the Key Factors Driving Growth in the AMD Market?

The growth in the Age-Related Macular Degeneration market is driven by several factors, including the rising aging population, increasing adoption of advanced treatment modalities, and the expanding availability of healthcare services globally. The growing focus on precision medicine and biomarker-driven therapies is leading to more targeted and effective treatments, further boosting market growth. Additionally, the increasing prevalence of lifestyle-related risk factors, such as diabetes and hypertension, which contribute to AMD progression, is fueling the demand for early interventions and preventive measures. The expansion of healthcare infrastructure, particularly in emerging economies, and the growing investment by pharmaceutical companies in ophthalmology research are also contributing to market growth. Furthermore, the introduction of reimbursement policies and patient assistance programs is making AMD treatments more accessible, driving higher treatment adoption rates across different demographics.

Report Scope

The report analyzes the Age-Related Macular Degeneration market, presented in terms of market value (US$). The analysis covers the key segments and geographic regions outlined below:

• Segments: Product (Eylea Age-related Macular Degeneration, Lucentis Age-related Macular Degeneration, Beovu Age-related Macular Degeneration, Other Products); Disease (Wet Age-related Macular Degeneration, Dry Age-related Macular Degeneration); Distribution Channel (Hospital Pharmacy Distribution Channels, Specialty Pharmacy Distribution Channels, Online Pharmacy Distribution Channels).
• Geographic Regions/Countries: World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Key Insights:

• Market Growth: Understand the significant growth trajectory of the Eylea Age-related Macular Degeneration segment, which is expected to reach US$8.9 Billion by 2032 with a CAGR of a 8.8%. The Lucentis Age-related Macular Degeneration segment is also set to grow at 7.6% CAGR over the analysis period.
• Regional Analysis: Gain insights into the U.S. market, valued at $3 Billion in 2025, and China, forecasted to grow at an impressive 12% CAGR to reach $4 Billion by 2032. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.

Why You Should Buy This Report:

• Detailed Market Analysis: Access a thorough analysis of the Global Age-Related Macular Degeneration Market, covering all major geographic regions and market segments.
• Competitive Insights: Get an overview of the competitive landscape, including the market presence of major players across different geographies.
• Future Trends and Drivers: Understand the key trends and drivers shaping the future of the Global Age-Related Macular Degeneration Market.
• Actionable Insights: Benefit from actionable insights that can help you identify new revenue opportunities and make strategic business decisions.

Key Questions Answered:

• How is the Global Age-Related Macular Degeneration Market expected to evolve by 2032?
• What are the main drivers and restraints affecting the market?
• Which market segments will grow the most over the forecast period?
• How will market shares for different regions and segments change by 2032?
• Who are the leading players in the market, and what are their prospects?

Report Features:

• Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2025 to 2032.
• In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
• Company Profiles: Coverage of players such as Adverum Biotechnologies Inc., Alkeus Pharmaceuticals Inc., Apellis Pharmaceuticals, Inc., Bausch & Lomb, Inc., Bayer AG and more.
• Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.

Some of the companies featured in this Age-Related Macular Degeneration market report include:

• Adverum Biotechnologies Inc.
• Alkeus Pharmaceuticals Inc.
• Apellis Pharmaceuticals, Inc.
• Bausch & Lomb, Inc.
• Bayer AG
• F. Hoffmann-La Roche AG
• Lupin Ltd.
• Novartis AG
• Outlook Therapeutics, Inc.
• Opthea Limited
• Regeneron Pharmaceuticals Inc.
• Ribomic Inc.
• Xbrane Biopharma AB

What Sets This Report Apart From Others?

• Grounded in Domain Expert Perspectives: Incorporates perspectives emerging from domain experts across industry, enterprise and academia, adding context beyond conventional published research.
• Captures Early Market Signals: Tracks shifts emerging through expert conversations, company activity and market-relevant discussions before they are fully reflected in traditional secondary research.
• Draws From a Broad, Validated Intelligence Base: Brings together insights from conference sessions, keynotes, panel discussions, blogs, corporate disclosures, annual reports, institutional publications and other validated sources.
• Connects Signals With Strategic Market Direction: Synthesizes these perspectives to identify where the market is moving, what is driving that movement and which developments are likely to matter most for strategy.
• Provides In-Depth Company Intelligence: Extends beyond market-level analysis to examine the companies participating in and shaping the competitive environment.
• Market Share Is Examined Where It Matters: A single global market share figure rarely tells the full story. Competitive structures can vary significantly across geographies. Where analytically relevant, our reports extend market share analysis into major regions with the level of detail tailored to the structure and dynamics of each market.